Genocea Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Genocea Biosciences generated cash of -$45,370,000, which is less than the previous year. Cash used in financing activities reached the amount of $5,957,000 last year.
Cash Flow
| 2012 | -12.68M | -460K | 18.91M |
|---|---|---|---|
| 2013 | -19.87M | -389K | 20.95M |
| 2014 | -27.60M | -28.57M | 64.02M |
| 2015 | -38.35M | -64.93M | 100.49M |
| 2016 | -41.83M | 50.71M | 1.28M |
| 2017 | -47.59M | 34.90M | -2.46M |
| 2018 | -41.23M | -131K | 55.45M |
| 2019 | -37.73M | -1.08M | 52.90M |
| 2020 | -41.65M | -2.55M | 83.84M |
| 2021 | -45.37M | -3.20M | 5.95M |
GNCA Cash Flow Statement (2012 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 80.4M | 40.75M | 26.67M | 12.58M | 27.42M | 17.25M | 20.05M | 12.20M | 11.51M | 5.74M |
Operating activities | ||||||||||
Net income | -33.19M | -43.71M | -38.95M | -27.81M | -56.71M | -49.57M | -42.48M | -35.29M | -20.80M | -13.36M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.55M | 1.13M | 1.09M | 1.08M | 1.51M | 1.81M | 1.05M | 469K | 318K | 300K |
Stock-based compensation expense | 3.63M | 1.97M | 1.83M | 2.15M | 4.23M | 4.14M | 3.84M | 2.90M | 672K | 307K |
| Deferred income tax benefit | 3.63M | 1.97M | 1.83M | 2.15M | 4.23M | 4.14M | 3.84M | 2.90M | 672K | 307K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -57K | 31K | -1.10M | -2.10M | 491K | 1.19M | -1.43M | 516K | 724K | 515K |
Cash generated by operating activities | -45.37M | -41.65M | -37.73M | -41.23M | -47.59M | -41.83M | -38.35M | -27.60M | -19.87M | -12.68M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -153K | -26.06M | -89.65M | -27.05M | 0 | 0 |
Investments In Property Plant And Equipment | -3.28M | -2.58M | -1.13M | -241K | -1.17M | -2.53M | -2.78M | -1.52M | -389K | -460K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -3.20M | -2.55M | -1.08M | -131K | 34.90M | 50.71M | -64.93M | -28.57M | -389K | -460K |
Financing activities | ||||||||||
Common Stock Issued | 11.34M | 83.83M | 54.66M | 55.45M | 246K | 815K | 95.18M | 61.93M | 15.25M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -23K | -134K | 0 | -535K | 0 | 0 | 0 | -10.40M | -4.24M | -1.16M |
Cash used in financing activities | 5.95M | 83.84M | 52.90M | 55.45M | -2.46M | 1.28M | 100.49M | 64.02M | 20.95M | 18.91M |
Net Change In Cash | 0 | 39.64M | 14.08M | 14.08M | -15.15M | 10.16M | -2.79M | 7.85M | 692K | 5.77M |
Cash at end of period | 80.4M | 80.4M | 40.75M | 26.67M | 12.27M | 27.42M | 17.25M | 20.05M | 12.20M | 11.51M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |